Detail of "22102-92-7"

Reference

Analgesic properties of a systemically administered synthetic dipeptide of 5-hydroxytryptophan

Analgesic properties of a systemically administered synthetic dipeptide of 5-hydroxytryptophan. Bodnar, Richard J.; Karpiak, Stephen E.; Mann, Phyllis E.; Tamir, Hadassah; Wilchek, Meir; Yoburns, Byron C. (Queens Coll., CUNY, New York, NY, USA). Peptides (Fayetteville, N. Y.), 7(6), 995-9 (English) 1986. CODEN: PPTDD5. ISSN: 0196-9781. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 23, 28 An apolar deriv. of 5-hydroxytryptophan (5-HTP) dipeptide, N-hexanoyl-5-HTP-5-HTP amide (5-HTP-HEX-DP) (I) [90829-99-5] was evaluated for its analgesic properties in rats following systemic administration. 5-HTP-HEX-DP (5-50 mg/kg) increased jump thresholds in a dose-dependent manner with peak analgesia occurring at 2.5 h after injection and lasting up to 5 h. In the tail-flick assay, 5-HTP-HEX-DP (20 mg/kg) produced an antinociceptive effect at 1 h post-injection using both high and low intensity levels of radiant heat. While 5-HTP-HEX-DP and morphine each elicited analgesia following acute administration, chronic (14 days) incremental dosing with 5-HTP-HEX-DP or morphine resulted in persistent analgesia in 5-HTP-HEX-DP-treated animals, and a loss of analgesia in morphine-treated rats. Thus, significant tolerance to morphine, but not 5-HTP-HEX-DP analgesia developed using this protocol. 22102-92-7 and 90829-99-5 are just another two chemicals used in this study. Hence, 5-HTP-HEX-DP is a systemically-active analgesic which fails to induce tolerance when administered daily for 14 days. .